Results 91 to 100 of about 4,252 (181)

Novel, Achiral 4‑Nitroimidazole Compounds with Potent Antitubercular Activity. [PDF]

open access: yesACS Omega
Matlala TB   +5 more
europepmc   +1 more source

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial. [PDF]

open access: yesSignal Transduct Target Ther
Chu N   +15 more
europepmc   +1 more source

Increasing Antimicrobial Resistance to First-Line Therapies in Chronic Endometritis: A 2020-2024 Cross-Sectional Study. [PDF]

open access: yesJ Clin Med
Cicinelli E   +10 more
europepmc   +1 more source

<i>In vitro</i> exposure to clofazimine can select for delamanid and pretomanid resistance in <i>Mycobacterium tuberculosis</i>. [PDF]

open access: yesAntimicrob Agents Chemother
Rupasinghe P   +15 more
europepmc   +1 more source

Impact of Lactobacillus johnsonii CNCM I-4884 on canine giardiasis: a probiotic-based approach. [PDF]

open access: yesParasit Vectors
Polack B   +8 more
europepmc   +1 more source

Epidemiology and management of nitroimidazole-refractory giardiasis. [PDF]

open access: yesJ Travel Med
Boté-Casamitjana A   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy